AHL Partners’s Exact Sciences EXAS Stock Holding History

AHL Partners’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-8,743	Closed	-$412K	–	1283
2017 Q3	$412K	Buy	+8,743	New	+$352K	0.01%	1098
2016 Q4	–	Sell	-29,792	Closed	-$553K	–	1080
2016 Q3	$553K	Buy	+29,792	New	+$525K	0.02%	804

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

AHL Partners's EXAS Position: Q4 2017 in Review

AHL Partners sold out of Exact Sciences (EXAS) in Q4 2017, closing a stake of 8,743 shares — an estimated $412K sold.

AHL Partners first reported a position in EXAS in Q3 2016 and held it in 2 quarters. The position peaked at $553K in Q3 2016. 318 funds tracked by Wall St. Rank hold EXAS as of Q4 2017.

AHL Partners reported no remaining Exact Sciences position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 8,743 Exact Sciences shares in Q4 2017, an estimated $412K.
AHL Partners first reported a position in Exact Sciences in Q3 2016 and held it in 2 quarters.
AHL Partners's Exact Sciences position peaked at $553K in Q3 2016.
318 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.